Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
S&P 500 Futures Decline In Premarket Trading; GXO Logistics, Celsius Holdings Lead
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 74% Gain
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Stifel analyst Bradley Canino maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $155.According to TipRanks data, the analyst has a success rate of 45.3%
Blueprint Announces the Hiring of Industry Veteran John Smelter to Medical Outpatient Team
Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines Corporation's (NASDAQ:BPMC) Business Is Yet to Catch Up With Its Share Price
Blueprint Prep's Annual $20,000 Medical School Scholarship Now Open for Submissions
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)
Blueprint Medicines (NASDAQ:BPMC) Has Debt But No Earnings; Should You Worry?
9 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing
Analysts Just Shipped A Sizeable Upgrade To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates